A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
about
The Use of Rat and Mouse Models in Bariatric Surgery ExperimentsMetabolic Inflammation-Differential Modulation by Dietary ConstituentsGlucagon-like peptide-1: The missing link in the metabolic clock?Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamusEffectiveness, tolerability and practical application of the newer generation anti-obesity medicationsHypoglycemic agents and potential anti-inflammatory activityIn Vivo Models for Incretin Research: From the Intestine to the Whole BodyThe GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityThe metabolic vascular syndrome - guide to an individualized treatmentWeight management in obesity - past and presentMedical Management of Diabesity: Do We Have Realistic Targets?Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.Hidden Obesity in Dialysis Patients: Clinical Implications.Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primatesUpdate and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.Central nervous system regulation of eating: Insights from human brain imagingShould family physicians prescribe medication for obesity? NO.A systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorders.Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice.The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.The significance of beige and brown fat in humans.Weight maintenance: challenges, tools and strategies for primary care physiciansAssociation of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysisProbiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial.Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experienceObesity Education Strategies for Cancer Prevention in Women's Health.Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trialElectronic Quality of Life Assessment Using Computer-Adaptive Testing.Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis.Exposure-response analyses of liraglutide 3.0 mg for weight management.Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels.Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
P2860
Q26740015-7ED06F10-360B-4463-A4C4-34C38A215FE3Q26748868-AF42AA5F-AA9F-4576-B423-1E00C5DFE6DDQ26749185-0FB2FFB1-2675-406C-BB83-8681D527AA41Q26749191-5FB836BE-62BD-4F9B-9521-21AB5D3FA3EEQ26750405-93327B2B-CDDC-4CF2-93CC-9BE6E3DF7EA8Q26750414-E67D76EA-B4A7-4E72-B33A-61294FDE4F7FQ26753185-61222C99-5B2B-4F83-900A-75D7FC60683AQ26765609-A35D0316-42FD-4C98-9102-9D33E65790C9Q26767142-9B6A1BC3-1A5F-4555-A220-6B04AFCA1853Q26774747-8EDC842F-5C64-467B-B4D0-800727357659Q30238940-C1ED0134-E37C-4969-9FE5-D3CEBEA8A5A5Q30250304-B2ADD215-687F-464C-A8FA-A2504B82BBB9Q30251435-496FD9A3-AABB-40A5-B3CD-D53B17E31322Q30368984-093AE8CE-1535-487E-A502-C5C0FAECCD15Q30392979-DF45955B-979A-4997-8556-DC2356DAD006Q30400748-C636B232-E0B9-451D-B372-F56256521533Q31044140-EFC83B2E-0299-4D71-AE73-E14BE3A86C92Q31079099-E22254A2-830A-4FF5-BD74-D25037ED1F4FQ33574945-2D4CA4EF-8A57-40B8-B8F4-5D4A47C027AAQ33619779-7216D5C4-C4AE-42EC-BA72-5D53D9218D96Q33656442-CFCF2184-97BD-4509-8DE8-760538BB337EQ33679277-059DE093-F1FE-4FB1-B3C0-10BB1B5A7DCFQ33750634-FE45CD70-3421-45A5-AF69-31998B6B417BQ33904190-CE0B7C41-741A-467E-A9E3-D9A69F220CF9Q35816619-6D23000E-5547-463B-9ED4-B8E90673D258Q36051581-07FFF36F-C3B3-4DE7-B682-0DC4998CC5A7Q36181692-E1C3E6A2-E5B9-4997-B5E4-A8689C2F46BBQ36291168-8BE9C4D6-C426-444E-BC3D-DB770A83B119Q36567721-B89B53F2-5EE6-4129-9344-7330BCFDB900Q37151164-EA98191F-2D92-4FF5-8870-53E9F79BC819Q37342085-69B4917D-B893-4894-AF99-864E825DD528Q37348394-6A348054-9699-4B3F-86FE-5AEA73F898C3Q37348898-0863DEA1-B603-4D99-8858-5BEB746726B7Q37349843-349AAFDB-8B80-4B55-87AA-69CE68D707D1Q37375632-8A4BBA53-3941-457F-B365-0368B5092E99Q37456235-4C79B42F-D1AC-44B3-B277-A5F45C033279Q37456906-3731C29B-99E3-4095-8C87-D929A143D5C2Q37501257-1373E4F6-28F0-4F4D-B617-3BCD827DF1EAQ37606430-24CEBA46-2015-4AD2-8061-A4E112EE468FQ37631924-C8EC113D-5501-4D09-AF81-C4F618B90DBF
P2860
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
@en
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
@nl
type
label
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
@en
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
@nl
prefLabel
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
@en
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
@nl
P2093
P50
P356
P1476
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
@en
P2093
Alfredo Halpern
Christine Bjørn Jensen
David C W Lau
Frank Greenway
John P H Wilding
Ken Fujioka
Rafael Violante Ortiz
SCALE Obesity and Prediabetes NN8022-1839 Study Group
P356
10.1056/NEJMOA1411892
P407
P577
2015-07-01T00:00:00Z